Withdrawn application: Zefylti, filgrastim, Date of withdrawal: 08/06/2023, Initial authorisation
Human medicines European public assessment report (EPAR): Eurartesim, piperaquine tetraphosphate,artenimol, Malaria, Date of authorisation: 27/10/2011, Revision: 13, Status: Authorised
COVID-19 public health emergency of international concern (2020-23)
Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi,Larotrectinib, decision type: , therapeutic area: , PIP number: P/0289/2022
Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, HIV Infections, Date of authorisation: 01/03/2004, Revision: 54, Status: Authorised
Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5
QRD Appendix V - Adverse-drug-reaction reporting details
Member states contact points for translations review
How to prepare and review a summary of product characteristics
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Gastrointestinal Stromal Tumors, Date of authorisation: 18/11/2021, Revision: 5, Status: Authorised